Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
1. To evaluate the toxicity and safety of a combination of bortezomib with arsenic
trioxide, ascorbic acid and high-dose melphalan in patients with multiple myeloma
2. To evaluate the efficacy of a combination of bortezomib with arsenic trioxide, ascorbic
acid and high-dose melphalan in patients with multiple myeloma
3. To determine the effects of bortezomib on melphalan pharmacokinetics